Dr. Reddys Laboratories Ltd.
BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1245.50
-24.30 (-1.91%) Dr Reddys Laboratories informs about press release
Date: 19-04-2016Dr Reddys Laboratories has informed about a Press Release dated April 19, 2016 titled ‘ZEMBRACE SymTouch (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the US’.
The above information is a part of company’s filings submitted to BSE.